ClinicalTrials.gg
CompletedNCT02052596Updated Apr 24, 2018Results posted

Study to Assess the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) When Co-administered With GSK Biologicals' Diphtheria, Tetanus and Pertussis Vaccine (Boostrix®) in Adults Aged 50 Years and Older

A Phase 3 interventional study of Herpes Zoster vaccine GSK 1437173A and Boostrix in Herpes Zoster, sponsored by GlaxoSmithKline. Completed at 13 sites in United States. Open to participants aged 50 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-04-24.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
935
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 46 studies testing shingrix in Herpes Zoster — 8 open to participants now, 11 under way, 3 of them phase 3. shingrix · Herpes Zoster.

Enrollment
10th of 46
935 · median 239
Started
2014
with 4 others
Phase 3
22 of 46
2 open now
Registered
12th of 46
by date
Lead sponsor
26 of 46
GlaxoSmithKline

Among the 46 studies testing shingrix in Herpes Zoster, this one is the 10th largest by enrollment, is one of 5 that started in 2014, is one of 22 in phase 3, and was the 12th registered.

Herpes Zoster

299 studies on the registry are indexed under Herpes Zoster; 55 are open to participants now.

Browse Herpes Zoster studies →

Open to participants now

8 of the 46 studies testing shingrix in Herpes Zoster are open now, in 5 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About shingrix

shingrix: first FDA approval 2017 (Shingrix). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 37 Herpes Zoster studies recruiting now, 26 (70%) set no upper age limit and 6 (16%) stop at 75 or younger; 3 take children under 18; 13 take healthy volunteers.

This study: 50 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 46 studies testing shingrix in Herpes Zoster, or all of them as a file.
02

Study summary

The purpose of this study is to assess immunogenicity, reactogenicity and safety of GSK Biologicals' HZ/su vaccine when its first dose is co-administered with the Boostrix® vaccine in adults aged 50 years or older compared to administration of vaccines separately.

03

Conditions studied

  • Herpes Zoster

Browse trials for

Keywords

  • Boostrix
  • Herpes zoster
  • Immunogenicity
  • Co-administration
  • Adults
  • Safety
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects who, in the opinion of the investigator, can and will comply with the requirements of the protocol.
  • A male or female aged 50 years or older at the time of the first vaccination with the study vaccine(s).
  • Written obtained from the subject.
  • Female subjects of non- may be enrolled in the study.

    • Non-childbearing potential is defined as pre-menarche, current tubal ligation, hysterectomy, ovariectomy or .
  • Female subjects of childbearing potential may be enrolled in the study, if the subject:

    • has practiced adequate for 30 days prior to vaccination, and
    • has a negative pregnancy test on the day of vaccination, and
    • has agreed to continue adequate contraception during the entire treatment period and for 2 months after completion of the vaccination series.

Exclusion criteria

Exclusion Criteria:

  • Use of any or non-registered product (drug or vaccine) other than the study vaccines within 30 days preceding the first dose of study vaccine, or planned use during the study period.
  • Chronic administration (defined as more than 14 consecutive days) of or other immune-modifying drugs within six months prior to the first vaccine dose (for , this will mean prednisone ≥ 20 mg/day, or equivalent). A prednisone dose of \< 20 mg/day is allowed. Inhaled, topical and intra-articular corticosteroids are allowed.
  • Administration or planned administration of a vaccine not foreseen by the study protocol within the period starting 30 days before the first dose of study vaccine(s) and ending 30 days after the last dose of study vaccine. This includes any type of vaccine such as (but not limited to) live, inactivated and subunit vaccines (e.g., inactivated and subunit influenza vaccines).
  • Administration of long-acting immune-modifying drugs (e.g. infliximab) within six months prior to the first vaccine dose or expected administration at any time during the study period.
  • Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational vaccine/product (pharmaceutical product or device).
  • Previous vaccination against VZV or HZ and/or planned administration during the study of an HZ or VZV vaccine (including an investigational or non-registered vaccine) other than the study vaccine.
  • History of HZ.
  • Vaccination against diphtheria, or tetanus in the last five years or planned vaccination against diphtheria or tetanus during the study period, other than the study vaccine(s).
  • Administration of a combined tetanus, diphtheria and pertussis (Tdap) vaccine at any time prior to study entry.
  • Any confirmed or suspected immunosuppressive or immunodeficient condition resulting from disease (e.g., , [HIV] infection) or immunosuppressive/cytotoxic therapy (e.g., medications used during cancer chemotherapy, organ transplantation or to treat disorders).
  • History of any reaction or likely to be exacerbated by any component of the vaccines including prior severe allergic reaction following tetanus-toxoid, diphtheria-toxoid or pertussis-containing vaccine.
  • Hypersensitivity to latex. Note: The investigational HZ/su vaccine does not contain latex.
  • Acute disease and/or fever at the time of enrolment.

    • Fever is defined as temperature ≥ 37.5°C /99.5°F by oral route. The preferred route for recording temperature in this study will be oral.
    • Subjects with a minor illness (such as mild diarrhea, mild upper respiratory infection) without fever may, be enrolled at the discretion of the investigator.
  • Administration of immunoglobulins and/or any blood products within the 3 months preceding the first dose of study vaccine or planned administration during the study period.
  • Pregnant or lactating female.
  • Female planning to become pregnant or planning to discontinue precautions before 2 months after the last dose of study vaccine.
  • Any condition which, in the opinion of the investigator, prevents the subject from participating in the study.
  • Any condition which, in the judgment of the investigator, would make intramuscular (IM) injection unsafe.
  • Encephalopathy (e.g. coma, decreased consciousness, prolonged seizures) not attributable to an identifiable cause within 7 days of administration of a previous pertussis antigen-containing vaccine.
  • Progressive or unstable neurologic disorder.
  • History of Arthus-type hypersensitivity reaction following a prior dose of a tetanus-toxoid containing vaccine within the last 10 years.
  • History of Guillain-Barré syndrome within 6 weeks of receipt of a prior vaccine containing tetanus toxoid.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
935 participants (actual)

Study arms

  • Experimental
    GSK1437173A Group

    Subjects received one injection of Boostrix vaccine and one injection of the GSK1437173A vaccine during the first visit and a second injection of the GSK1437173A vaccine during the third visit, two months later.

    Biological: Herpes Zoster vaccine GSK 1437173A · Biological: Boostrix

  • Active comparator
    Control Group

    Subjects received all vaccines separately i.e. one injection of Boostrix vaccine at the first visit, one injection of the GSK1437173A vaccine at the third visit and a second injection of the GSK1437173A vaccine at the fourth visit, all two months apart.

    Biological: Herpes Zoster vaccine GSK 1437173A · Biological: Boostrix

Interventions

  • 2 doses administered intramuscularly (IM) in the deltoid region of the non-dominant arm at Visit Day 0 and Visit Month 2 for Co-Ad group and at Visit Month 2 and Visit Month 4 for Control group.

  • BiologicalBoostrix

    1 dose administered intramuscularly (IM) in the deltoid region of the dominant arm at Visit Day 0 for both Co-Ad and Control groups.

06

What researchers measure

Primary outcomes

  1. Number of Subjects With a Vaccine Response for Anti-glycoprotein E (Anti-gE) in GSK1437173A Group

    This outcome was required only for the GSK1437173A Group. Vaccine response defined as: For initially seronegative subjects, antibody concentration at post-vaccination ≥ 4 fold the cut-off for Anti-gE (4x97 mIU/mL); For initially seropositive subjects, antibody concentration at post-vaccination ≥ 4 fold the pre-vaccination antibody concentration.

    Time frame: At 1 month post-Dose 2 (Month 3)

  2. Antibody Concentrations Against Glycoprotein E (Anti-gE)

    Antibody concentrations against glycoprotein E (gE) have been assessed by enzyme-linked immunosorbent assay (ELISA), presented as geometric mean concentrations (GMCs) and expressed in milli-international units per milliliter (mIU/mL). The reference seropositivity cut-off was an anti-gE antibody concentration greater than or equal to (≥) 97 mIU/mL.

    Time frame: At 1 month post-Dose 2 (Month 3 for GSK1437173A Group adn Month 5 for Control Group)

  3. Antibody Concentrations Against Pertussis Toxoid (Anti-PT), Filamentous Hemagglutinin (Anti-FHA) and Pertactin (Anti-PRN) Antigens

    Anti-PT, anti-FHA and anti-PRN antibody concentrations have been assessed by enzyme-linked immunosorbent assay (ELISA), presented as geometric mean concentrations (GMCs) and expressed in international units per milliliter (IU/mL).

    Time frame: At 1 month post-Dose 1 (Month 1)

  4. Antibody Concentrations Against Diphteria (Anti-D) and Tetanus (Anti-T) Antigens

    Anti-PT, anti-FHA and anti-PRN antibody concentrations have been assessed by enzyme-linked immunosorbent assay (ELISA), presented as geometric mean concentrations (GMCs) and expressed in international units per milliliter (IU/mL).

    Time frame: At 1 month post-Dose 1 (Month 1)

Secondary outcomes

  1. Number of Subjects With Any and Grade 3 Solicited Local Symptoms, by Dose

    Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond (\>) 100 millimeters (mm). "0" Implied that no data was applicable for the GSK1437173A Group at Dose 3, since it received only 2 vaccine doses

    Time frame: During the 7-day (Days 0-6) post-vaccination period following each dose and across doses

  2. Number of Subjects With Any and Grade 3 Solicited Local Symptoms, by Study Vaccine

    Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond (\>) 100 millimeters (mm). "0" implies that: 1. No data were applicable for the GSK1437173A vaccine at Dose 1 for the Control Group, as it was only administered at Doses 2 and 3 in this group 2. No data were applicable for the Boostrix vaccine at Doses 2 and 3 for any of the groups, as it was only administered at Dose 1 for both the groups. 3. No data were applicable for the GSK1437173A Group at Dose 3, since it received only 2 vaccine doses.

    Time frame: During the 7-day (Days 0-6) post-vaccination period following each dose and across doses

  3. Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms, by Dose

    Assessed solicited general symptoms were fatigue, gastrointestinal (symptoms included nausea, vomiting, diarrhoea and/or abdominal pain), headache, myalgia, shivering and fever \[defined as oral, axillary, rectal or tympanic temperature equal to or above (≥) 37.5 degrees Celsius (°C)\]. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptoms = symptoms that prevented normal activity. Grade 3 fever = temperature above (\>) 39.0 °C. Related = general symptom assessed by the investigator as causally related to vaccination. "0" Implied that no data was applicable for the GSK1437173A Group at Dose 3, since it received only 2 vaccine doses

    Time frame: During the 7-day (Days 0-6) post-vaccination period following each dose and across doses

  4. Number of Days With Solicited Symptoms

    The number of days with local and general symptoms have been assessed during the solicited post-vaccination period. "0" Implied that no data was applicable for the GSK1437173A Group at Dose 3, since it received only 2 vaccine doses

    Time frame: During the 7-day (Days 0-6) post-vaccination period following each dose and across doses

  5. Number of Subjects With Any and Related Potential Immune Mediated Diseases (pIMDs)

    Potential immune-mediated diseases (pIMDs) are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology. Related = pIMDs assessed by the investigator as causally related to the study vaccination.

    Time frame: From first vaccination up to study end (Day 0 to Month 14)

  6. Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs)

    An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination.

    Time frame: Within the 30-day (Days 0-29) post-vaccination period

  7. Number of Subjects With Any Serious Adverse Events (SAEs)

    Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life-threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.

    Time frame: From first vaccination up to study end (Day 0 to Month 14)

07

Results

Posted Apr 24, 2018
Limitations and caveats
At the time of posting this record, only the safety and demography results until 1-month post-last vaccination (Co-ad group Month 3 and Control group Month 5) were available. The record will be updated once immunogenicity results become available.

Participant flow

Not all subjects who were enrolled started the study due to elimination from statistical analyses or no vaccination received.

Active Phase
Participant flow — Active Phase
MilestoneGSK1437173A GroupControl Group
Started412418
Completed396398
Not completed1620
Withdrew: Adverse event32
Withdrew: Lost to follow-up811
Withdrew: Protocol violation12
Withdrew: Withdrawal by subject34
Withdrew: Enrolled in error10
Withdrew: Lost due to crohn's disease01
Safety Phase
Participant flow — Safety Phase
MilestoneGSK1437173A GroupControl Group
Started412418
Completed385383
Not completed2735
Withdrew: Adverse event63
Withdrew: Lost to follow-up1118
Withdrew: Protocol violation12
Withdrew: Withdrawal by subject811
Withdrew: Enrolled in error10
Withdrew: Lost due to crohn's disease01

Outcome measures

PrimaryNumber of Subjects With a Vaccine Response for Anti-glycoprotein E (Anti-gE) in GSK1437173A Group

This outcome was required only for the GSK1437173A Group. Vaccine response defined as: For initially seronegative subjects, antibody concentration at post-vaccination ≥ 4 fold the cut-off for Anti-gE (4x97 mIU/mL); For initially seropositive subjects, antibody concentration at post-vaccination ≥ 4 fold the pre-vaccination antibody concentration.

Time frame:
At 1 month post-Dose 2 (Month 3)
Reported as:
Count of participants · Participants
Number of Subjects With a Vaccine Response for Anti-glycoprotein E (Anti-gE) in GSK1437173A Group
ParticipantsGSK1437173A Group
Number of Subjects With a Vaccine Response for Anti-glycoprotein E (Anti-gE) in GSK1437173A Group361
PrimaryAntibody Concentrations Against Glycoprotein E (Anti-gE)

Antibody concentrations against glycoprotein E (gE) have been assessed by enzyme-linked immunosorbent assay (ELISA), presented as geometric mean concentrations (GMCs) and expressed in milli-international units per milliliter (mIU/mL). The reference seropositivity cut-off was an anti-gE antibody concentration greater than or equal to (≥) 97 mIU/mL.

Time frame:
At 1 month post-Dose 2 (Month 3 for GSK1437173A Group adn Month 5 for Control Group)
Reported as:
Geometric mean · mIU/mL
Antibody Concentrations Against Glycoprotein E (Anti-gE)
mIU/mLGSK1437173A GroupControl Group
Antibody Concentrations Against Glycoprotein E (Anti-gE)51687.7 (48425.1 to 55170.1)57998.6 (54456.9 to 61770.6)
Statistical analysis
  • GSK1437173A Group vs Control Group · Adjusted gmc ratio: 1.11 · 95% CI 1.02 to 1.21Adjustment for baseline concentration and age - pooled variance.
PrimaryAntibody Concentrations Against Pertussis Toxoid (Anti-PT), Filamentous Hemagglutinin (Anti-FHA) and Pertactin (Anti-PRN) Antigens

Anti-PT, anti-FHA and anti-PRN antibody concentrations have been assessed by enzyme-linked immunosorbent assay (ELISA), presented as geometric mean concentrations (GMCs) and expressed in international units per milliliter (IU/mL).

Time frame:
At 1 month post-Dose 1 (Month 1)
Reported as:
Geometric mean · IU/mL
Antibody Concentrations Against Pertussis Toxoid (Anti-PT), Filamentous Hemagglutinin (Anti-FHA) and Pertactin (Anti-PRN) Antigens
IU/mLGSK1437173A GroupControl Group
Anti-PT41.1 (36.2 to 46.7)53.9 (47.4 to 61.4)
Anti-FHA309.3 (276.4 to 346.0)399.4 (359.1 to 444.3)
Anti-PRN222.6 (186.3 to 266.0)278.1 (232.9 to 332.0)
Statistical analysis
  • GSK1437173A Group vs Control Group · Adjusted gmc ratio: 1.17 · 95% CI 1.00 to 1.36Ancova model: adjustment for baseline concentration - pooled variance.
  • GSK1437173A Group vs Control Group · Adjusted gmc ratio: 1.24 · 95% CI 1.07 to 1.44Adjustment for baseline concentration - pooled variance.
  • GSK1437173A Group vs Control Group · Adjusted gmc ratio: 1.27 · 95% CI 1.02 to 1.58Adjustment for baseline concentration - pooled variance.
PrimaryAntibody Concentrations Against Diphteria (Anti-D) and Tetanus (Anti-T) Antigens

Anti-PT, anti-FHA and anti-PRN antibody concentrations have been assessed by enzyme-linked immunosorbent assay (ELISA), presented as geometric mean concentrations (GMCs) and expressed in international units per milliliter (IU/mL).

Time frame:
At 1 month post-Dose 1 (Month 1)
Reported as:
Geometric mean · IU/mL
Antibody Concentrations Against Diphteria (Anti-D) and Tetanus (Anti-T) Antigens
IU/mLGSK1437173A GroupControl Group
Anti-D2.2 (1.9 to 2.6)2.5 (2.1 to 3.0)
Anti-T8.7 (7.8 to 9.7)10.1 (9.0 to 11.4)
Statistical analysis
  • GSK1437173A Group vs Control Group · Difference in seropositivity rate: -0.10 · 95% CI -3.03 to 2.85
  • GSK1437173A Group vs Control Group · Difference in seropositivity rate: 0.01 · 95% CI -1.18 to 1.27
SecondaryNumber of Subjects With Any and Grade 3 Solicited Local Symptoms, by Dose

Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond (\>) 100 millimeters (mm). "0" Implied that no data was applicable for the GSK1437173A Group at Dose 3, since it received only 2 vaccine doses

Time frame:
During the 7-day (Days 0-6) post-vaccination period following each dose and across doses
Reported as:
Count of participants · Participants
Number of Subjects With Any and Grade 3 Solicited Local Symptoms, by Dose
ParticipantsGSK1437173A GroupControl Group
Any Pain, Dose 1315156
Grade 3 Pain, Dose 1263
Any Redness, Dose 111918
Grade 3 Redness, Dose 111
Any Swelling, Dose 17922
Grade 3 Swelling, Dose 111
Any Pain, Dose 2289299
Grade 3 Pain, Dose 21521
Any Redness, Dose 2116102
Grade 3 Redness, Dose 253
Any Swelling, Dose 28367
Grade 3 Swelling, Dose 210
Any Pain, Dose 30282
Grade 3 Pain, Dose 3024
Any Redness, Dose 30101
Grade 3 Redness, Dose 303
Any Swelling, Dose 3076
Grade 3 Swelling, Dose 300
Any Pain, Across doses346357
Grade 3 Pain, Across doses3939
Any Redness, Across doses167148
Grade 3 Redness, Across doses67
Any Swelling, Across doses124115
Grade 3 Swelling, Across doses21
SecondaryNumber of Subjects With Any and Grade 3 Solicited Local Symptoms, by Study Vaccine

Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond (\>) 100 millimeters (mm). "0" implies that: 1. No data were applicable for the GSK1437173A vaccine at Dose 1 for the Control Group, as it was only administered at Doses 2 and 3 in this group 2. No data were applicable for the Boostrix vaccine at Doses 2 and 3 for any of the groups, as it was only administered at Dose 1 for both the groups. 3. No data were applicable for the GSK1437173A Group at Dose 3, since it received only 2 vaccine doses.

Time frame:
During the 7-day (Days 0-6) post-vaccination period following each dose and across doses
Reported as:
Count of participants · Participants
Number of Subjects With Any and Grade 3 Solicited Local Symptoms, by Study Vaccine
ParticipantsGSK1437173A GroupControl Group
Any Pain, Boostrix vaccine, Dose 1183156
Grade 3 Pain, Boostrix vaccine, Dose 183
Any Pain, GSK1437173A vaccine, Dose 12900
Grade 3 Pain, GSK1437173A vaccine, Dose 1200
Any Redness, Boostrix vaccine, Dose 13118
Grade 3 Redness, Boostrix vaccine, Dose 101
Any Redness, GSK1437173A vaccine, Dose 11080
Grade 3 Redness, GSK1437173A vaccine, Dose 110
Any Swelling, Boostrix vaccine, Dose 12322
Grade 3 Swelling, Boostrix vaccine, Dose 101
Any Swelling, GSK1437173A vaccine, Dose 1670
Grade 3 Swelling, GSK1437173A vaccine, Dose 110
Any Pain, Boostrix vaccine, Dose 200
Grade 3 Pain, Boostrix vaccine, Dose 200
Any Pain, GSK1437173A vaccine, Dose 2289299
Grade 3 Pain, GSK1437173A vaccine, Dose 21521
Any Redness, Boostrix vaccine, Dose 200
Grade 3 Redness, Boostrix vaccine, Dose 200
Any Redness, GSK1437173A vaccine, Dose 2116102
Grade 3 Redness, GSK1437173A vaccine, Dose 253
Any Swelling, Boostrix vaccine, Dose 200
Grade 3 Swelling, Boostrix vaccine, Dose 200
Any Swelling, GSK1437173A vaccine, Dose 28367
Grade 3 Swelling, GSK1437173A vaccine, Dose 210
Any Pain, Boostrix vaccine, Dose 300
Grade 3 Pain, Boostrix vaccine, Dose 300
Any Pain, GSK1437173A vaccine, Dose 30282
Grade 3 Pain, GSK1437173A vaccine, Dose 3024
Any Redness, Boostrix vaccine, Dose 300
Grade 3 Redness, Boostrix vaccine, Dose 300
Any Redness, GSK1437173A vaccine, Dose 30101
Grade 3 Redness, GSK1437173A vaccine, Dose 303
Any Swelling, Boostrix vaccine, Dose 300
Grade 3 Swelling, Boostrix vaccine, Dose 300
Any Swelling, GSK1437173A vaccine, Dose 3076
Grade 3 Swelling, GSK1437173A vaccine, Dose 300
Any Pain, Boostrix vaccine, Across doses183156
Grade 3 Pain, Boostrix vaccine, Across doses83
Any Pain, GSK1437173A vaccine, Across doses339344
Grade 3 Pain, GSK1437173A vaccine, Across doses3437
Any Redness, Boostrix vaccine, Across doses3118
Grade 3 Redness, Boostrix vaccine, Across doses01
Any Redness, GSK1437173A vaccine, Across doses163144
Grade 3 Redness, GSK1437173A vaccine, Across doses66
Any Swelling, Boostrix vaccine, Across doses2322
Grade 3 Swelling, Boostrix vaccine, Across doses01
Any Swelling, GSK1437173A vaccine, Across doses117109
Grade 3 Swelling, GSK1437173A vaccine,Across doses20
SecondaryNumber of Subjects With Any, Grade 3 and Related Solicited General Symptoms, by Dose

Assessed solicited general symptoms were fatigue, gastrointestinal (symptoms included nausea, vomiting, diarrhoea and/or abdominal pain), headache, myalgia, shivering and fever \[defined as oral, axillary, rectal or tympanic temperature equal to or above (≥) 37.5 degrees Celsius (°C)\]. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptoms = symptoms that prevented normal activity. Grade 3 fever = temperature above (\>) 39.0 °C. Related = general symptom assessed by the investigator as causally related to vaccination. "0" Implied that no data was applicable for the GSK1437173A Group at Dose 3, since it received only 2 vaccine doses

Time frame:
During the 7-day (Days 0-6) post-vaccination period following each dose and across doses
Reported as:
Count of participants · Participants
Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms, by Dose
ParticipantsGSK1437173A GroupControl Group
Any Fatigue, Dose 112965
Grade 3 Fatigue, Dose 1127
Related Fatigue, Dose 18837
Any Gastrointestinal, Dose 15235
Grade 3 Gastrointestinal, Dose 123
Related Gastrointestinal, Dose 12516
Any Headache, Dose 110660
Grade 3 Headache, Dose 173
Related Headache, Dose 17432
Any Myalgia, Dose 1177102
Grade 3 Myalgia, Dose 1124
Related Myalgia, Dose 113476
Any Shivering, Dose 16416
Grade 3 Shivering, Dose 163
Related Shivering, Dose 1488
Any Temperature, Dose 1367
Grade 3 Temperature, Dose 120
Related Temperature, Dose 1265
Any Fatigue, Dose 2137110
Grade 3 Fatigue, Dose 2229
Related Fatigue, Dose 210174
Any Gastrointestinal, Dose 25146
Grade 3 Gastrointestinal, Dose 255
Related Gastrointestinal, Dose 23428
Any Headache, Dose 29982
Grade 3 Headache, Dose 2108
Related Headache, Dose 27454
Any Myalgia, Dose 2160155
Grade 3 Myalgia, Dose 21716
Related Myalgia, Dose 2122116
Any Shivering, Dose 27938
Grade 3 Shivering, Dose 2124
Related Shivering, Dose 26027
Any Temperature, Dose 25123
Grade 3 Temperature, Dose 220
Related Temperature, Dose 23216
Any Fatigue, Dose 30130
Grade 3 Fatigue, Dose 3014
Related Fatigue, Dose 3092
Any Gastrointestinal, Dose 3054
Grade 3 Gastrointestinal, Dose 303
Related Gastrointestinal, Dose 3037
Any Headache, Dose 3095
Grade 3 Headache, Dose 308
Related Headache, Dose 3069
Any Myalgia, Dose 30164
Grade 3 Myalgia, Dose 3019
Related Myalgia, Dose 30124
Any Shivering, Dose 3065
Grade 3 Shivering, Dose 3011
Related Shivering, Dose 3050
Any Temperature, Dose 3043
Grade 3 Temperature, Dose 301
Related Temperature, Dose 3028
Any Fatigue, Across doses186192
Grade 3 Fatigue, Across doses3027
Related Fatigue, Across doses143134
Any Gastrointestinal, Across doses8597
Grade 3 Gastrointestinal, Across doses79
Related Gastrointestinal, Across doses5162
Any Headache, Across doses152158
Grade 3 Headache, Across doses1615
Related Headache, Across doses118108
Any Myalgia, Across doses227243
Grade 3 Myalgia, Across doses2732
Related Myalgia, Across doses176186
Any Shivering, Across doses112100
Grade 3 Shivering, Across doses1816
Related Shivering, Across doses8672
Any Temperature, Across doses7263
Grade 3 Temperature, Across doses31
Related Temperature, Across doses4841
SecondaryNumber of Days With Solicited Symptoms

The number of days with local and general symptoms have been assessed during the solicited post-vaccination period. "0" Implied that no data was applicable for the GSK1437173A Group at Dose 3, since it received only 2 vaccine doses

Time frame:
During the 7-day (Days 0-6) post-vaccination period following each dose and across doses
Reported as:
Mean · Days
Number of Days With Solicited Symptoms
DaysGSK1437173A GroupControl Group
Pain, Dose 13.2 (2.0 to 4.0)2.6 (2.0 to 3.0)
Pain, Dose 22.8 (2.0 to 4.0)2.9 (2.0 to 4.0)
Pain, Dose 3—2.7 (2.0 to 3.0)
Redness, Dose 13.3 (2.0 to 5.0)3.0 (2.0 to 5.0)
Redness, Dose 23.2 (2.0 to 4.0)3.2 (2.0 to 4.0)
Redness, Dose 3—2.9 (2.0 to 4.0)
Swelling, Dose 13.3 (2.0 to 5.0)3.5 (2.0 to 5.0)
Swelling, Dose 23.1 (2.0 to 4.0)3.0 (2.0 to 4.0)
Swelling, Dose 3—2.9 (2.0 to 4.0)
Fatigue, Dose 12.4 (1.0 to 3.0)2.5 (1.0 to 4.0)
Fatigue, Dose 22.3 (1.0 to 3.0)2.7 (1.0 to 3.0)
Fatigue, Dose 3—2.6 (1.0 to 4.0)
Gastrointestinal, Dose 12.3 (1.0 to 4.0)2.1 (1.0 to 3.0)
Gastrointestinal, Dose 22.0 (1.0 to 2.0)2.3 (1.0 to 3.0)
Gastrointestinal, Dose 3—1.9 (1.0 to 3.0)
Headache, Dose 11.8 (1.0 to 2.0)2.2 (1.0 to 2.0)
Headache, Dose 21.9 (1.0 to 2.0)2.1 (1.0 to 3.0)
Headache, Dose 3—2.0 (1.0 to 2.0)
Myalgia, Dose 12.9 (2.0 to 4.0)2.3 (1.0 to 3.0)
Myalgia, Dose 22.7 (2.0 to 3.5)2.9 (1.0 to 4.0)
Myalgia, Dose 3—2.7 (1.0 to 3.0)
Shivering, Dose 11.6 (1.0 to 2.0)2.3 (1.0 to 3.0)
Shivering, Dose 21.6 (1.0 to 2.0)1.6 (1.0 to 2.0)
Shivering, Dose 3—1.5 (1.0 to 1.0)
Temperature, Dose 11.7 (1.0 to 2.0)2.4 (1.0 to 3.0)
Temperature, Dose 21.6 (1.0 to 2.0)1.5 (1.0 to 1.0)
Temperature, Dose 3—1.5 (1.0 to 2.0)
SecondaryNumber of Subjects With Any and Related Potential Immune Mediated Diseases (pIMDs)

Potential immune-mediated diseases (pIMDs) are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology. Related = pIMDs assessed by the investigator as causally related to the study vaccination.

Time frame:
From first vaccination up to study end (Day 0 to Month 14)
Reported as:
Count of participants · Participants
Number of Subjects With Any and Related Potential Immune Mediated Diseases (pIMDs)
ParticipantsGSK1437173A GroupControl Group
Any pIMD(s)00
Related pIMD(s)00
SecondaryNumber of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs)

An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination.

Time frame:
Within the 30-day (Days 0-29) post-vaccination period
Reported as:
Count of participants · Participants
Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs)
ParticipantsGSK1437173A GroupControl Group
Any AE(s)105118
Grade 3 AE(s)1015
Related AE(s)2731
SecondaryNumber of Subjects With Any Serious Adverse Events (SAEs)

Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life-threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.

Time frame:
From first vaccination up to study end (Day 0 to Month 14)
Reported as:
Count of participants · Participants
Number of Subjects With Any Serious Adverse Events (SAEs)
ParticipantsGSK1437173A GroupControl Group
Number of Subjects With Any Serious Adverse Events (SAEs)2131

Adverse events

Collected over Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: within the 30-day (Days 0-29) post-vaccination period; SAEs: from first vaccination up to study end at Month 14.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
GSK1437173A Group4/412 (1%)21/412 (5.1%)368/412 (89.3%)
Control Group5/418 (1.2%)31/418 (7.4%)380/418 (90.9%)
Most frequent serious events
Showing 10 of 56
Most frequent serious events
EventGSK1437173A GroupControl Group
Cardiac failure congestiveCardiac disorders4/4121/418
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders1/4123/418
OsteoarthritisMusculoskeletal and connective tissue disorders2/4122/418
PneumoniaInfections and infestations1/4122/418
AnaemiaBlood and lymphatic system disorders1/4120/418
Acute myocardial infarctionCardiac disorders1/4121/418
Cardiac arrestCardiac disorders1/4120/418
Chest painGeneral disorders1/4120/418
CholelithiasisHepatobiliary disorders1/4120/418
Bacterial sepsisInfections and infestations1/4120/418
Most frequent other events
Most frequent other events
EventGSK1437173A GroupControl Group
PainGeneral disorders346/412357/418
MyalgiaMusculoskeletal and connective tissue disorders228/412243/418
FatigueGeneral disorders186/412192/418
ErythemaSkin and subcutaneous tissue disorders167/412148/418
HeadacheNervous system disorders153/412159/418
SwellingGeneral disorders124/412115/418
ChillsGeneral disorders112/412102/418
Gastrointestinal disorderGastrointestinal disorders85/41297/418
PyrexiaGeneral disorders74/41264/418

Baseline characteristics

Age, Continuous
Age, Continuous(Years)GSK1437173A GroupControl GroupTotal
Mean63.4 ± 8.463.1 ± 9.063.25 ± 8.7
Sex: Female, Male
Sex: Female, Male(Participants)GSK1437173A GroupControl GroupTotal
Female222225447
Male190193383
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)GSK1437173A GroupControl GroupTotal
Geographic ancestry — African Heritage/African American415394
Geographic ancestry — American Indian or Alaskan Native112
Geographic ancestry — Asian - Central/South Asian Heritage011
Geographic ancestry — Asian - East Asian Heritage011
Geographic ancestry — Asian - Japanese Heritage101
Geographic ancestry — White - Arabic/North African Heritage303
Geographic ancestry — White - Caucasian/European Heritage364357721
Geographic ancestry — Mixed Origin257
08

Study locations

13 sites
  • GSK Investigational Site
    Tucson, Arizona 85704, United States
  • GSK Investigational Site
    Tucson, Arizona 85712, United States
  • GSK Investigational Site
    San Diego, California 92108, United States
  • GSK Investigational Site
    Stockbridge, Georgia 30281, United States
  • GSK Investigational Site
    Meridian, Idaho 83642, United States
  • GSK Investigational Site
    Lewiston, Maine 04240, United States
  • GSK Investigational Site
    Las Vegas, Nevada 89104, United States
  • GSK Investigational Site
    Charlotte, North Carolina 28209, United States
  • GSK Investigational Site
    Salisbury, North Carolina 28114, United States
  • GSK Investigational Site
    Uniontown, Pennsylvania 15401, United States
  • GSK Investigational Site
    Warwick, Rhode Island 02886, United States
  • GSK Investigational Site
    Greer, South Carolina 29650, United States
  • GSK Investigational Site
    Richmond, Virginia 23294, United States
09

References and documents

Publications

  • Strezova A, Lal H, Enweonye I, Campora L, Beukelaers P, Segall N, Heineman TC, Schuind AE, Oostvogels L. The adjuvanted recombinant zoster vaccine co-administered with a tetanus, diphtheria and pertussis vaccine in adults aged >/=50 years: A randomized trial. Vaccine. 2019 Sep 16;37(39):5877-5885. doi: 10.1016/j.vaccine.2019.08.001. Epub 2019 Aug 20. PubMed 31443993 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2014 to primary completion in Jun 2015, 16 months.

Results were first posted in Apr 2018, 2 years 10 months after primary completion. A results delay was requested in Jun 2016.

Of 33 industry-sponsored phase 3 interventional studies under Herpes Zoster, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 45. This study's 16 months is close to that.

Counting every sponsor, half of 40 studies reached it within 16 months; a quarter within 10 and three quarters within 45.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 23, 2014
First posted
Feb 3, 2014
StartActual
Feb 7, 2014
Primary completionActual
Jun 16, 2015
CompletionActual
Apr 21, 2016
Results delay requested
Jun 16, 2016
Results first posted
Apr 24, 2018
Last update
Apr 24, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 24, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02052596
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Feb 3, 2014
Start date
Feb 7, 2014
Primary completion
Jun 16, 2015
Completion
Apr 21, 2016
Results posted
Apr 24, 2018
Last update
Apr 24, 2018

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Shingrix · Boostrix

Start the discussion